Wealth Enhancement Trust Services’s TG Therapeutics TGTX Stock Holding History

Wealth Enhancement Trust Services’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$769	Buy	+14	New	+$573	﹤0.01%	1173

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wealth Enhancement Trust Services's TGTX Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in TG Therapeutics (TGTX) in Q2 2026: 14 shares worth $769. The stake represents ﹤0.01% of the portfolio and ranks #1173 among its holdings.

291 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Wealth Enhancement Trust Services held 14 shares of TG Therapeutics worth $769 as of Q2 2026.
TG Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
TG Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1173 holding.
291 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.